Literature DB >> 33744974

Systematic in vitro specificity profiling reveals nicking defects in natural and engineered CRISPR-Cas9 variants.

Karthik Murugan1,2, Shravanti K Suresh1, Arun S Seetharam3, Andrew J Severin3, Dipali G Sashital1,2.   

Abstract

Cas9 is an RNA-guided endonuclease in the bacterial CRISPR-Cas immune system and a popular tool for genome editing. The commonly used Streptococcus pyogenes Cas9 (SpCas9) is relatively non-specific and prone to off-target genome editing. Other Cas9 orthologs and engineered variants of SpCas9 have been reported to be more specific. However, previous studies have focused on specificity of double-strand break (DSB) or indel formation, potentially overlooking alternative cleavage activities of these Cas9 variants. In this study, we employed in vitro cleavage assays of target libraries coupled with high-throughput sequencing to systematically compare cleavage activities and specificities of two natural Cas9 variants (SpCas9 and Staphylococcus aureus Cas9) and three engineered SpCas9 variants (SpCas9 HF1, HypaCas9 and HiFi Cas9). We observed that all Cas9s tested could cleave target sequences with up to five mismatches. However, the rate of cleavage of both on-target and off-target sequences varied based on target sequence and Cas9 variant. In addition, SaCas9 and engineered SpCas9 variants nick targets with multiple mismatches but have a defect in generating a DSB, while SpCas9 creates DSBs at these targets. Overall, these differences in cleavage rates and DSB formation may contribute to varied specificities observed in genome editing studies.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 33744974      PMCID: PMC8053117          DOI: 10.1093/nar/gkab163

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  72 in total

1.  Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells.

Authors:  Daesik Kim; Jungeun Kim; Junho K Hur; Kyung Wook Been; Sun-Heui Yoon; Jin-Soo Kim
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

2.  Nucleosomes impede Cas9 access to DNA in vivo and in vitro.

Authors:  Max A Horlbeck; Lea B Witkowsky; Benjamin Guglielmi; Joseph M Replogle; Luke A Gilbert; Jacqueline E Villalta; Sharon E Torigoe; Robert Tjian; Jonathan S Weissman
Journal:  Elife       Date:  2016-03-17       Impact factor: 8.140

3.  Optimized CRISPR guide RNA design for two high-fidelity Cas9 variants by deep learning.

Authors:  Daqi Wang; Chengdong Zhang; Bei Wang; Bin Li; Qiang Wang; Dong Liu; Hongyan Wang; Yan Zhou; Leming Shi; Feng Lan; Yongming Wang
Journal:  Nat Commun       Date:  2019-09-19       Impact factor: 14.919

4.  Amplification-free long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity.

Authors:  Ida Höijer; Josefin Johansson; Sanna Gudmundsson; Chen-Shan Chin; Ignas Bunikis; Susana Häggqvist; Anastasia Emmanouilidou; Maria Wilbe; Marcel den Hoed; Marie-Louise Bondeson; Lars Feuk; Ulf Gyllensten; Adam Ameur
Journal:  Genome Biol       Date:  2020-12-01       Impact factor: 13.583

5.  In vitro enzymology of Cas9.

Authors:  Carolin Anders; Martin Jinek
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

6.  High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity.

Authors:  Vikram Pattanayak; Steven Lin; John P Guilinger; Enbo Ma; Jennifer A Doudna; David R Liu
Journal:  Nat Biotechnol       Date:  2013-08-11       Impact factor: 54.908

7.  Distinct patterns of Cas9 mismatch tolerance in vitro and in vivo.

Authors:  Becky X H Fu; Robert P St Onge; Andrew Z Fire; Justin D Smith
Journal:  Nucleic Acids Res       Date:  2016-05-19       Impact factor: 16.971

8.  Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9.

Authors:  Pan Tao; Xiaorong Wu; Venigalla Rao
Journal:  Sci Adv       Date:  2018-02-14       Impact factor: 14.136

9.  Target-dependent nickase activities of the CRISPR-Cas nucleases Cpf1 and Cas9.

Authors:  Becky Xu Hua Fu; Justin D Smith; Ryan T Fuchs; Megumu Mabuchi; Jennifer Curcuru; G Brett Robb; Andrew Z Fire
Journal:  Nat Microbiol       Date:  2019-03-04       Impact factor: 17.745

Review 10.  The promise and challenge of therapeutic genome editing.

Authors:  Jennifer A Doudna
Journal:  Nature       Date:  2020-02-12       Impact factor: 49.962

View more
  3 in total

1.  A detailed protocol for expression, purification, and activity determination of recombinant SaCas9.

Authors:  Franziska Flottmann; Greta Marie Pohl; Jan Gummert; Hendrik Milting; Andreas Brodehl
Journal:  STAR Protoc       Date:  2022-04-05

Review 2.  CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives.

Authors:  Yau-Tuen Chan; Yuanjun Lu; Junyu Wu; Cheng Zhang; Hor-Yue Tan; Zhao-Xiang Bian; Ning Wang; Yibin Feng
Journal:  Theranostics       Date:  2022-04-11       Impact factor: 11.600

Review 3.  CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.

Authors:  Guofang Chen; Tingyi Wei; Hui Yang; Guoling Li; Haisen Li
Journal:  Cells       Date:  2022-09-22       Impact factor: 7.666

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.